Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
65 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Astex Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Astex Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Astex Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Astex Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Astex Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Astex Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Astex Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Astex Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Astex Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Astex Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Astex Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Astex Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Astex Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Astex Pharmaceuticals, Inc. Snapshot 6 Astex Pharmaceuticals, Inc. Overview 6 Key Information 6 Key Facts 6 Astex Pharmaceuticals, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Astex Pharmaceuticals, Inc. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Combination Treatment Modalities 13 Pipeline Products - Out-Licensed Products 14 Out-Licensed Products/Combination Treatment Modalities 15 Astex Pharmaceuticals, Inc. - Pipeline Products Glance 16 Astex Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Astex Pharmaceuticals, Inc. - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Astex Pharmaceuticals, Inc. - Drug Profiles 20 AT-13387 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 AT-7519 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 AT-9283 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 SGI-110 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 (decitabine + E-7727) 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 AT-13148 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 AT-26893 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 AT-IAP 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecules for Undisclosed Indication 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecules to Activate PKM2 for Cancer 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecules to Inhibit AXL Kinase for Hematological Tumor 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Inhibit MetAP2 for Oncology 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules to Inhibit PAK1 for Colon Cancer 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Small Molecules to Inhibit RNaseH for HIV 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecules to Inhibit TNIK for Colorectal Cancer 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Tumour Cell Metabolism Program 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Astex Pharmaceuticals, Inc. - Pipeline Analysis 43 Astex Pharmaceuticals, Inc. - Pipeline Products by Target 43 Astex Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 45 Astex Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 46 Astex Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 47 Astex Pharmaceuticals, Inc. - Recent Pipeline Updates 49 Astex Pharmaceuticals, Inc. - Dormant Projects 60 Astex Pharmaceuticals, Inc. - Discontinued Pipeline Products 62 Discontinued Pipeline Product Profiles 62 amuvatinib 62 Astex Pharmaceuticals, Inc. - Locations And Subsidiaries 63 Head Office 63 Other Locations & Subsidiaries 63 Appendix 64 Methodology 64 Coverage 64 Secondary Research 64 Primary Research 64 Expert Panel Validation 64 Contact Us 65 Disclaimer 65
List of Tables Astex Pharmaceuticals, Inc., Key Information 6 Astex Pharmaceuticals, Inc., Key Facts 6 Astex Pharmaceuticals, Inc. - Pipeline by Indication, 2014 9 Astex Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 11 Astex Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 12 Astex Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014 13 Astex Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 14 Astex Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 15 Astex Pharmaceuticals, Inc. - Phase II, 2014 16 Astex Pharmaceuticals, Inc. - Phase I, 2014 17 Astex Pharmaceuticals, Inc. - Preclinical, 2014 18 Astex Pharmaceuticals, Inc. - Discovery, 2014 19 Astex Pharmaceuticals, Inc. - Pipeline by Target, 2014 44 Astex Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 45 Astex Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 46 Astex Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 48 Astex Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 49 Astex Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 60 Astex Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 62 Astex Pharmaceuticals, Inc., Subsidiaries 63
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
